The Multi‐Kinase Inhibitor GZD824 (Olverembatinib) Shows Pre‐Clinical Efficacy in Endometrial Cancer
ABSTRACT Objective Endometrial cancer is one of the few cancers for which mortality is still increasing. A lack of treatment options remains a major challenge, particularly for some subtypes of the disease. GZD824, also known as olverembatinib, is a multi‐kinase inhibitor previously investigated in...
Saved in:
Main Authors: | , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Wiley
2025-01-01
|
Series: | Cancer Medicine |
Online Access: | https://doi.org/10.1002/cam4.70531 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|